A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil
Abstract Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30 mg. Methods This was a randomiz...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-04-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13195-018-0368-9 |
| _version_ | 1819065534378934272 |
|---|---|
| author | Terence Fullerton Brendon Binneman William David Marielle Delnomdedieu James Kupiec Peter Lockwood Jessica Mancuso Jeffrey Miceli Joanne Bell |
| author_facet | Terence Fullerton Brendon Binneman William David Marielle Delnomdedieu James Kupiec Peter Lockwood Jessica Mancuso Jeffrey Miceli Joanne Bell |
| author_sort | Terence Fullerton |
| collection | DOAJ |
| description | Abstract Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30 mg. Methods This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of SAM-760 30 mg once daily (QD) for 12 weeks in subjects with AD on a stable regimen of donepezil 5 to 10 mg QD. The study included an interim analysis with stopping rules for futility or efficacy after 180 subjects completed the week 12 visit. Up to 342 subjects with AD (Mini-Mental State Examination (MMSE) score 10–24) and neuropsychiatric symptoms (Neuropsychiatric Inventory (NPI) total score ≥ 10) were to be enrolled if the study continued after the interim analysis. After a 4-week, single-blind, placebo run-in period, subjects entered the 12-week double-blind period and were randomized to either SAM-760 or placebo. The primary and key secondary efficacy endpoints were the change from baseline in Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog13) and NPI total scores. Mixed models for repeated measures were used to analyze the data. Results At the interim analysis, when 186 subjects had been randomized and 163 had completed the week 12 visit, the study met futility criteria and was stopped. The mean week 12 treatment difference was 0.70 points (P = 0.43) for ADAS-cog13 and 2.19 points (P = 0.20) for NPI score, both of which were numerically in favor of placebo. Other secondary endpoints did not demonstrate any significant benefit for SAM-760. In total, 46.2% of SAM-760 subjects reported adverse events (AE) versus 44.7% for placebo, and there were 5 (5.5%) serious AEs in the SAM-760 group versus 3 (3.2%) for placebo. There were two deaths, one prior to randomization and one in the SAM-760 group (due to a traffic accident during washout of active treatment). Conclusions SAM-760 was safe and well tolerated, but there was no benefit of SAM-760 on measures of cognition, neuropsychiatric symptoms, or daily function. Differences in trial design, study population, region, or pharmacological profile may explain differences in outcome compared with other 5-HT6 receptor antagonists. Trial registration Clinicaltrials.gov, NCT01712074. Registered 19 October 2012. |
| first_indexed | 2024-12-21T15:47:59Z |
| format | Article |
| id | doaj.art-cd2894dc000748f6acf781381a6cf8a7 |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-12-21T15:47:59Z |
| publishDate | 2018-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-cd2894dc000748f6acf781381a6cf8a72022-12-21T18:58:19ZengBMCAlzheimer’s Research & Therapy1758-91932018-04-0110111010.1186/s13195-018-0368-9A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezilTerence Fullerton0Brendon Binneman1William David2Marielle Delnomdedieu3James Kupiec4Peter Lockwood5Jessica Mancuso6Jeffrey Miceli7Joanne Bell8Pfizer Global Product DevelopmentPfizer Internal Medicine Research UnitPfizer Internal Medicine Research UnitPfizer Internal Medicine Research UnitPfizer Global Product DevelopmentPfizer Global Product DevelopmentPfizer Early Clinical ResearchPfizer Internal Medicine Research UnitPfizer Global Product DevelopmentAbstract Background Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor saturation in humans at a dose of 30 mg. Methods This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of SAM-760 30 mg once daily (QD) for 12 weeks in subjects with AD on a stable regimen of donepezil 5 to 10 mg QD. The study included an interim analysis with stopping rules for futility or efficacy after 180 subjects completed the week 12 visit. Up to 342 subjects with AD (Mini-Mental State Examination (MMSE) score 10–24) and neuropsychiatric symptoms (Neuropsychiatric Inventory (NPI) total score ≥ 10) were to be enrolled if the study continued after the interim analysis. After a 4-week, single-blind, placebo run-in period, subjects entered the 12-week double-blind period and were randomized to either SAM-760 or placebo. The primary and key secondary efficacy endpoints were the change from baseline in Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog13) and NPI total scores. Mixed models for repeated measures were used to analyze the data. Results At the interim analysis, when 186 subjects had been randomized and 163 had completed the week 12 visit, the study met futility criteria and was stopped. The mean week 12 treatment difference was 0.70 points (P = 0.43) for ADAS-cog13 and 2.19 points (P = 0.20) for NPI score, both of which were numerically in favor of placebo. Other secondary endpoints did not demonstrate any significant benefit for SAM-760. In total, 46.2% of SAM-760 subjects reported adverse events (AE) versus 44.7% for placebo, and there were 5 (5.5%) serious AEs in the SAM-760 group versus 3 (3.2%) for placebo. There were two deaths, one prior to randomization and one in the SAM-760 group (due to a traffic accident during washout of active treatment). Conclusions SAM-760 was safe and well tolerated, but there was no benefit of SAM-760 on measures of cognition, neuropsychiatric symptoms, or daily function. Differences in trial design, study population, region, or pharmacological profile may explain differences in outcome compared with other 5-HT6 receptor antagonists. Trial registration Clinicaltrials.gov, NCT01712074. Registered 19 October 2012.http://link.springer.com/article/10.1186/s13195-018-0368-9Alzheimer’s DiseaseSerotonin5-HT |
| spellingShingle | Terence Fullerton Brendon Binneman William David Marielle Delnomdedieu James Kupiec Peter Lockwood Jessica Mancuso Jeffrey Miceli Joanne Bell A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil Alzheimer’s Research & Therapy Alzheimer’s Disease Serotonin 5-HT |
| title | A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| title_full | A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| title_fullStr | A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| title_full_unstemmed | A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| title_short | A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| title_sort | phase 2 clinical trial of pf 05212377 sam 760 in subjects with mild to moderate alzheimer s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil |
| topic | Alzheimer’s Disease Serotonin 5-HT |
| url | http://link.springer.com/article/10.1186/s13195-018-0368-9 |
| work_keys_str_mv | AT terencefullerton aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT brendonbinneman aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT williamdavid aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT marielledelnomdedieu aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jameskupiec aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT peterlockwood aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jessicamancuso aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jeffreymiceli aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT joannebell aphase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT terencefullerton phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT brendonbinneman phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT williamdavid phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT marielledelnomdedieu phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jameskupiec phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT peterlockwood phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jessicamancuso phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT jeffreymiceli phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil AT joannebell phase2clinicaltrialofpf05212377sam760insubjectswithmildtomoderatealzheimersdiseasewithexistingneuropsychiatricsymptomsonastabledailydoseofdonepezil |